Investor Days Thuringia 2021
On June 15 and 16, 2021, the Stiftung für Technologie, Innovation und Forschung Thüringen (STIFT) and bm-t beteiligungsmanagement thüringen gmbh (bm|t) organized the “Investor Days Thuringia” (IDT) in Erfurt – in digital format due to the corona pandemic.
We were happy that Dynamic42 received one of the coveted lecture places. A total of 23 start-ups and 13 growth companies presented their business concepts on the digital IDT pitch stage on 15 June. Ahead 67 projects from Germany, Austria, Israel, Italy, New Zealand, Spain, South Africa, the Czech Republic, Hungary, and Uruguay applied.
Our managing directors Dr. Martin Raasch and Dr. Knut Rennert presented Dynamic42 GmbH in a five-minute pitch in the category “Growth Companies”. In addition to the Dynamic42 organ-on-chip models and current market figures, Knut and Martin talked about the company’s goals and outlined the strategic positioning of the coming years.
On June 15, we were also represented with our digital booth in the Innovation Arena. Here we were able to establish further contacts with investors and multipliers and initiate the first potential cooperation.
On the second day, we were able to intensively exchange and network with representatives of the local economy, start-up scene and contact persons for funding instruments in a round-table format.
We would like to thank the organizers of the “Investor Days” for the successful event. This event has brought us plenty positive feedback and make new contacts with investors possible.
About the Investor Days Thuringia 2021
From June 15 to 16, innovation-driven start-ups and growth companies met with national and international industries and investors. As part of this online event, around 600 participants exchanged their view on latest technologies and trends from various industries. The whole program was broadcast live from the Erfurt Multifunctional Arena.
Picture: Mobile Event App
More interesting articles:
In this article, we will discuss common issues observed when working with biochips made of PDMS, most commonly used alternatives, and desired properties for biochip materials. But most importantly, we will present alternative biochips showing low adsorptions rates but also unique biocompatibility for high grade drug screening.Read More
In this blog we will provide you with an introduction to the drug development process from target validation to post-market surveillance to give you a better understanding on how new drugs are being developed.Read More